Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Gene Therapy for Heart Failure Market: Genotype-Specific Cardiomyopathy Treatment Demand, AAV-Based Cardiac Delivery Growth, and Calcium-Handling Restoration Technology Adoption to Drive Strong Market Expansion Through 2035

The global Gene Therapy for Heart Failure Market was valued at USD 2,451.8 million in 2025 and is projected to expand at a strong CAGR of 15.2%, reaching approximately USD 8,761.1 million by 2035. This growth trajectory is being driven by sustained clinical demand for genotype-specific cardiomyopathy treatment, growing utilization of AAV-based cardiac delivery platforms, and continued advancement of calcium-handling restoration technology. The market comprises a substantial clinical-stage pipeline including AB-1002, SRD-002, TN-201, TN-401, and multiple LX-series candidates, with no broadly approved gene therapy specifically for conventional heart failure currently available.

The market’s strong 15.2% CAGR reflects the field’s transition from generic cardiac function enhancement toward genotype-specific cardiomyopathy treatment, generating structured demand from cardiovascular centers above discretionary specialty pharmaceutical demand growth as this remains primarily a pipeline and emerging therapeutic market. Sustained clinical progress across BAG3-associated dilated cardiomyopathy, PKP2-associated arrhythmogenic cardiomyopathy, and MYBPC3-positive hypertrophic cardiomyopathy continues to demonstrate the field’s shift toward molecularly defined treatment approaches. Coverage extending across multiple therapeutic strategies, vector platforms, and delivery routes underscores the breadth of clinical and manufacturing infrastructure now supporting this category as it advances from Phase 1 through pivotal development stages.

Executive Snapshot

How does genotype-specific cardiomyopathy treatment demand drive the gene therapy for heart failure market?
Cardiovascular treatment centers increasingly focus gene therapy development on molecularly defined cardiomyopathy subtypes, including BAG3-associated dilated cardiomyopathy, PKP2-associated arrhythmogenic cardiomyopathy, and MYBPC3-positive hypertrophic cardiomyopathy, establishing genotype-specific treatment as a defining feature of current clinical development. As genetic testing continues to identify eligible patient populations, procurement associated with genotype-specific treatment is expected to remain a leading category through the forecast period.

What role does AAV-based cardiac delivery growth play in market expansion?
Biopharmaceutical developers continue to rely on adeno-associated virus vectors, including AAV1, AAV6, and AAV9 serotypes, for cardiac-directed gene delivery, sustaining structured demand from developers pursuing established viral vector platforms above emerging non-viral delivery alternatives.

How does calcium-handling restoration technology adoption sustain market growth?
Biopharmaceutical developers continue to advance SERCA2A-targeted and related calcium-handling restoration candidates such as SRD-002, sustaining structured demand above conventional generic cardiac function enhancement approaches. Continued clinical investment in this specific therapeutic strategy is generating demand from developers pursuing mechanistically defined heart failure treatment.

What is driving demand for gene therapy in intracoronary and intramyocardial delivery applications?
Developers pursuing intracoronary infusion delivery, consistent with AB-1002’s evaluation approach in its Phase 2 GenePHIT trial which completed enrollment of more than 170 participants across 64 sites in 12 countries, continue to establish this delivery route alongside emerging systemic intravenous administration approaches.

How does anti-fibrotic and anti-remodeling therapeutic strategy demand sustain the market?
Biopharmaceutical developers increasingly pursue anti-fibrotic and anti-remodeling gene therapy strategies alongside contractility enhancement approaches, sustaining structured demand from developers pursuing comprehensive heart failure disease modification beyond symptomatic improvement alone.

Which gene therapy for heart failure market segments are growing fastest?
The fastest-growing segments include genotype-specific cardiomyopathy treatment for BAG3, PKP2, and MYBPC3-associated disease, systemic intravenous delivery approaches, Phase 2 and pivotal-stage clinical candidates, and combination approaches alongside guideline-directed medical therapy.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: Gene Therapy for Heart Failure Market

  • Cardiac contractility enhancement sustaining the leading share of current therapeutic strategy activity: Calcium-handling restoration and sarcomere protein restoration approaches continue to represent the most clinically advanced therapeutic strategies across the category.
  • AB-1002 sustaining the leading share of clinical development activity among current candidates: This program’s substantial Phase 2 GenePHIT trial enrollment continues to anchor a significant portion of overall gene therapy for heart failure development activity.
  • Genotype-specific cardiomyopathy programs sustaining structured demand above generic function-enhancement approaches: BAG3, PKP2, and MYBPC3-directed programs continue to represent an increasingly important area of pipeline differentiation.
  • AAV vector platforms sustaining the dominant delivery technology across the category: AAV1, AAV6, and AAV9 serotypes continue to represent the leading delivery platform relative to adenoviral, lentiviral, and non-viral alternatives.
  • Intracoronary delivery sustaining an established administration approach alongside emerging systemic delivery: Consistent with AB-1002’s evaluation approach, this delivery route continues to anchor current clinical activity as newer programs explore intravenous administration.
  • Phase 1 through pivotal-stage clinical development sustaining the entirety of current market activity: The absence of a broadly approved heart failure-specific gene therapy continues to concentrate all market activity within clinical-stage development.

Market Segmentation: Gene Therapy for Heart Failure Market

By Therapy Type
  • Gene Addition
  • Gene Replacement
  • Gene Overexpression
  • Gene Silencing
  • Gene Editing
  • Gene Correction
  • RNA-Mediated Gene Modulation
  • Multigene Therapy
  • Other Genetic Therapies
By Target
  • SERCA2A
  • PP1 Inhibitor-1 / I-1
  • PKP2
  • BAG3
  • MYBPC3
  • LAMP2B
  • FXN / Frataxin
  • PLN
  • DSP
  • TNNI3
  • Others
By Delivery Platform
  • Adeno-Associated Virus (AAV)
    • AAV1
    • AAV2
    • AAV6
    • AAV9
    • AAVrh.74
    • Other AAV Serotypes
  • Adenoviral Vectors
  • Lentiviral Vectors
  • Non-Viral Delivery
  • Lipid Nanoparticles
  • Other Emerging Delivery Platforms
By Gene Therapy Product
  • AB-1002 / Umiposgene parvec
  • SRD-002 / AAV1.SERCA2a
  • RP-A701
  • TN-201
  • TN-401
  • LX2006
  • LX2020
  • LX2021
  • LX2022
  • Others
By NYHA Functional Class
  • Class I
  • Class II
  • Class III
  • Class IV
By Disease Stage
  • Early-Stage Heart Failure
  • Moderate Heart Failure
  • Advanced Heart Failure
  • End-Stage Heart Failure
  • Pre-Symptomatic Genetic Cardiomyopathy
  • Symptomatic Genetic Cardiomyopathy
By Route of Administration
  • Intracoronary
  • Intravenous
  • Intramyocardial
  • Intrapericardial
  • Other Cardiac Delivery Routes
By Ejection Fraction
  • LVEF ≤25%
  • LVEF 26–35%
  • LVEF 36–40%
  • LVEF 41–49%
  • LVEF ≥50%
By Product Development Stage
  • Commercially Available Products
  • Phase III Products
  • Phase II Products
  • Phase I Products
  • Preclinical Products
By End User
  • Hospitals
  • Cardiovascular Centers
  • Heart Failure Specialty Centers
  • Cardiac Catheterization Centers
  • Academic Medical Centers
  • Specialty Gene Therapy Centers
  • Research Institutes
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: Gene Therapy for Heart Failure Market

  1. Sustained clinical progress across genetically defined cardiomyopathy subtypes driving genotype-specific treatment demand: BAG3, PKP2, and MYBPC3-directed programs continue to sustain structured demand above the discretionary specialty pharmaceutical baseline.
  2. Growing reliance on established AAV vector platforms supporting continued cardiac delivery technology investment: AAV1, AAV6, and AAV9 serotype applications continue to attract structured developer investment given established viral vector manufacturing infrastructure.
  3. Continued clinical investment in calcium-handling restoration supporting mechanistically defined treatment adoption: SERCA2A-targeted approaches continue to differentiate structured demand from generic cardiac function enhancement strategies.
  4. Sustained interest in intracoronary and emerging systemic delivery routes supporting administration technology development: Established intracoronary infusion approaches continue to anchor current clinical activity as newer programs explore intravenous administration.
  5. Growing developer focus on anti-fibrotic and anti-remodeling strategies supporting comprehensive disease modification: These approaches continue to attract structured investment pursuing treatment beyond symptomatic contractility improvement alone.
  6. Maturing clinical pipeline supporting an approaching wave of pivotal trial initiations: A growing number of Phase I and Phase II candidates continues to focus treatment center and payer attention on the category’s next phase of clinical maturation.

Regional Outlook: Gene Therapy for Heart Failure Market

  • North America: The United States accounts for the largest share of regional demand, supported by extensive cardiovascular center infrastructure, broad biopharmaceutical investment, and leading clinical trial activity in gene therapy for heart failure development; regional treatment centers continue to expand specialized capacity to accommodate this activity.
  • Europe: Germany, the United Kingdom, and France anchor regional demand, supported by growing specialized cardiovascular center capacity and consistent clinical trial participation, including multinational participation in the GenePHIT trial; this demand base is expected to remain broadly stable through the forecast period.
  • Asia-Pacific: Japan, China, and South Korea represent some of the fastest-growing regional markets as regional biopharmaceutical developers expand their own cardiovascular gene therapy pipelines; regional cardiovascular centers continue to invest in the specialized infrastructure required to support this expansion.
  • Latin America: Brazil and Mexico represent an emerging regional demand base as specialized cardiovascular centers begin to participate in gene therapy for heart failure clinical trials; this segment is expected to follow a steady, if more gradual, growth trajectory through 2035.

Competitive Landscape: Gene Therapy for Heart Failure Market

Key Players
AavantiBio (Solid Biosciences Inc.), Renovacor, Inc. (Rocket Pharmaceuticals, Inc.), Rocket Pharmaceuticals, Inc., Tenaya Therapeutics, Inc., Lexeo Therapeutics, Inc., Asklepios BioPharmaceutical, Inc. (Bayer AG), Ultragenyx Pharmaceutical Inc.

  • Rocket Pharmaceuticals, Inc. [March 2026] — confirmed continued enrollment progress for its Phase 2 GenePHIT trial evaluating AB-1002, with the company noting completed enrollment of more than 170 participants across 64 sites in 12 countries.
  • Lexeo Therapeutics, Inc. [December 2025] — reported continued clinical development of its genotype-specific cardiomyopathy gene therapy pipeline, with the company noting sustained investigator interest in molecularly defined treatment approaches.
  • Tenaya Therapeutics, Inc. [September 2025] — confirmed continued clinical progress for its cardiac gene therapy candidates, with the company reporting structured investor interest in its AAV-based cardiac delivery platform.

Consultant POV

The Gene Therapy for Heart Failure Market’s strong 15.2% CAGR from USD 2,451.8 million in 2025 toward approximately USD 8,761.1 million by 2035 is anchored in sustained genotype-specific cardiomyopathy treatment demand, growing AAV-based cardiac delivery activity, and continued calcium-handling restoration technology adoption. Sustained clinical and manufacturing investment from companies including Rocket Pharmaceuticals, Inc., Lexeo Therapeutics, Inc., and Tenaya Therapeutics, Inc. confirms the Gene Therapy for Heart Failure Market will sustain strong growth through 2035.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report